Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMRX Immuneering	$6.04 +23.6%	$3.58	$1.06 ▼ $6.13	$218.28M	0.37	1.26 million shs	2.39 million shs
IOBT IO Biotech	$1.72 -1.4%	$1.70	$0.66 ▼ $2.79	$114.63M	0.44	1.26 million shs	1.02 million shs
MOLN Molecular Partners	$4.52 +23.2%	$3.68	$3.36 ▼ $7.60	$191.52M	1.1	6,260 shs	8,982 shs
MRSN Mersana Therapeutics	$7.53 -2.9%	$7.84	$5.21 ▼ $70.75	$37.71M	0.83	160,241 shs	68,658 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMRX Immuneering	0.00%	+30.05%	+20.44%	+217.53%	+357.01%
IOBT IO Biotech	0.00%	-19.44%	-15.53%	+43.80%	+6.10%
MOLN Molecular Partners	0.00%	+6.36%	-6.21%	-7.25%	-39.65%
MRSN Mersana Therapeutics	0.00%	+8.24%	-3.76%	-12.01%	-80.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMRX Immuneering	3.572 of 5 stars	3.3	4.0	0.0	1.9	5.0	0.6
IOBT IO Biotech	3.1766 of 5 stars	3.7	3.0	0.0	2.6	2.5	0.6
MOLN Molecular Partners	2.3309 of 5 stars	3.8	2.0	0.0	2.9	0.0	0.6
MRSN Mersana Therapeutics	4.2153 of 5 stars	3.5	4.0	4.1	1.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMRX Immuneering	2.60	Moderate Buy	$13.25	119.30% Upside
IOBT IO Biotech	3.33	Buy	$8.67	405.34% Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	165.49% Upside
MRSN Mersana Therapeutics	3.00	Buy	$56.60	652.06% Upside

Current Analyst Ratings Breakdown

Latest MRSN, IOBT, MOLN, and IMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/14/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$250.00 ➝ $36.00
8/14/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$125.00 ➝ $30.00
8/13/2025	MRSN Mersana Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
8/12/2025	IOBT IO Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $4.00
6/18/2025	IMRX Immuneering	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $10.00
6/18/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/18/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/5/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMRX Immuneering	$320K	685.77	N/A	N/A	$1.33 per share	4.54
IOBT IO Biotech	N/A	N/A	N/A	N/A	$0.71 per share	N/A
MOLN Molecular Partners	$5.65M	32.30	N/A	N/A	$3.99 per share	1.13
MRSN Mersana Therapeutics	$34.77M	1.08	N/A	N/A	($1.92) per share	-3.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMRX Immuneering	-$61.04M	-$1.89	N/A	N/A	N/A	N/A	-146.28%	-117.22%	11/12/2025 (Estimated)
IOBT IO Biotech	-$95.49M	-$1.58	N/A	N/A	N/A	N/A	-281.82%	-169.29%	11/11/2025 (Estimated)
MOLN Molecular Partners	-$61.39M	-$1.92	N/A	N/A	N/A	N/A	-42.20%	-38.12%	8/25/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$14.62	N/A	N/A	N/A	-212.94%	-990.16%	-54.85%	11/12/2025 (Estimated)

Latest MRSN, IOBT, MOLN, and IMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2025	H1 2025	MOLN Molecular Partners	-$0.53	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	IOBT IO Biotech	-$0.35	-$0.40	-$0.05	-$0.40	N/A	N/A
8/13/2025	Q2 2025	IMRX Immuneering	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/13/2025	Q2 2025	MRSN Mersana Therapeutics	-$3.75	-$4.08	-$0.33	-$4.87	$6.06 million	$3.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMRX Immuneering	N/A	3.70	3.70
IOBT IO Biotech	4.22	1.96	1.96
MOLN Molecular Partners	N/A	15.28	15.28
MRSN Mersana Therapeutics	N/A	1.35	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMRX Immuneering	67.65%
IOBT IO Biotech	54.76%
MOLN Molecular Partners	26.55%
MRSN Mersana Therapeutics	93.92%

Insider Ownership

Company	Insider Ownership
IMRX Immuneering	22.90%
IOBT IO Biotech	2.30%
MOLN Molecular Partners	5.93%
MRSN Mersana Therapeutics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMRX Immuneering	60	36.32 million	28.00 million	Not Optionable
IOBT IO Biotech	30	N/A	N/A	Not Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
MRSN Mersana Therapeutics	150	4.99 million	4.34 million	Optionable

MRSN, IOBT, MOLN, and IMRX Headlines

Recent News About These Companies

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of "Buy" from Analysts

August 24 at 2:11 AM | americanbankingnews.com

Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet

August 22 at 10:55 AM | zacks.com

Q3 Earnings Estimate for MRSN Issued By Leerink Partnrs

August 19, 2025 | americanbankingnews.com

Q3 EPS Forecast for Mersana Therapeutics Lifted by Analyst

August 18, 2025 | americanbankingnews.com

Research Analysts Offer Predictions for MRSN Q3 Earnings

August 17, 2025 | americanbankingnews.com

Mersana Therapeutics (NASDAQ:MRSN) Price Target Cut to $36.00 by Analysts at Truist Financial

August 16, 2025 | americanbankingnews.com

Mersana Therapeutics price target adjusted to $36 at Truist after reverse split

August 14, 2025 | msn.com

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call Transcript

August 14, 2025 | insidermonkey.com

Mersana Therapeutics Reports Q2 2025 Financial Results

August 14, 2025 | msn.com

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call Transcript

August 14, 2025 | msn.com

Mersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)

August 13, 2025 | msn.com

Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

Mersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

August 13, 2025 | finanznachrichten.de

Mersana Misses Fiscal Q2 Revenue Target

August 13, 2025 | theglobeandmail.com

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

August 13, 2025 | finance.yahoo.com

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

August 13, 2025 | zacks.com

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

August 13, 2025 | globenewswire.com

Mersana Therapeutics Q2 2025 Earnings Preview

August 12, 2025 | msn.com

A Look at Mersana Therapeutics's Upcoming Earnings Report

August 12, 2025 | benzinga.com

Earnings To Watch: Mersana Therapeutics Inc (MRSN) Reports Q2 2025 Result

August 12, 2025 | finance.yahoo.com

Mersana Therapeutics (NASDAQ:MRSN) Stock Price Down 5.3% - Here's What Happened

July 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRSN, IOBT, MOLN, and IMRX Company Descriptions

Immuneering NASDAQ:IMRX

$6.04 +1.15 (+23.56%)

As of 03:47 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

IO Biotech NASDAQ:IOBT

$1.72 -0.03 (-1.44%)

As of 03:46 PM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Molecular Partners NASDAQ:MOLN

$4.52 +0.85 (+23.16%)

As of 03:46 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Mersana Therapeutics NASDAQ:MRSN

$7.53 -0.22 (-2.89%)

As of 03:47 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time